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ABSTRACT
Introduction
Genetic mosaicism underlies many inherited and acquired cutaneous disorders. Despite the barriers
to genetic analysis of mosaic disorders, next generation sequencing has led to substantial progress
in understanding their pathogenesis, which has significant implications for clinical management and
genetic counselling. Advances in paired and deep sequencing technologies in particular have made
study of mosaic disorders more feasible. In this study, we aim to utilize next generation sequencing
technologies in order to evaluate the genetic cause of three mosaic cutaneous disorders:
epidermolytic acanthoma (EA), progressive symmetric erythrokeratodermia (PSEK), and mosaic
childhood acantholytic dyskeratosis.

Methods
Using genomic DNA extracted from paraffin-embedded samples from departmental archives of EA,
we evaluated a discovery cohort using whole-exome sequencing (WES) and assessed remaining
samples using Sanger sequencing screening and restriction fragment length polymorphism (RFLP)
analysis. We analyzed blood and saliva DNA from cases of PSEK referred from academic
dermatologists via WES and verified mutations via Sanger sequencing. We isolated and cultured
keratinocytes from a case of mosaic childhood acantholytic dyskeratosis and performed paired RNA
sequencing in comparison to blood RNA.

Results
DNA from 16/20 cases of EA in our sample was of sufficient quality for PCR amplification. WES of
genomic DNA from lesional tissue revealed KRT10 c.466C>T, p.Arg156Cys mutations in 2/3 samples
submitted for examination. RFLP analysis of these samples, as well as 8 additional samples
confirmed the mutations identified via WES and identified 4 additional cases with Arg156
mutations. In sum, 6/11 screened cases of EA demonstrated hotspot mutation in KRT10.
Additionally, all three cases of progressive symmetric erythrokeratodermia had compound
heterozygous mutations of the ABCA12 gene. One case had missense mutations on both copies of
the ABCA12 gene (c.2531A>G, p.D844G; c.5812C>T, p.P1938S). Another case had a nonsense
mutation on one copy of ABCA12 (c.5787T>G, p.Y1929*) and a missense mutation on the other
(c.6852G>C, p.E2284D). A third case had a frameshift mutation (c.2033_2036delATCA,
p.N678Rfs*10) on one copy of ABCA12 and a splice site mutation (c.2866-8T>A) on the other.
Finally, paired RNA sequencing of cultured keratinocytes from lesional tissue of a case of mosaic
acantholytic dyskeratosis revealed a somatic mutation in GJB2 (c.T83A, p.L28H) which was absent in
both of the patient's parents.

Conclusions
In this work, we present evidence for the genetic mechanism of three mosaic cutaneous conditions.
Our findings of hotspot mutations in the Arg156 position of KRT10 in EA support the hypothesis that
it is a somatic mosaic form of epidermolytic ichthyosis. Our finding of ABCA12 mutations in PSEK
combined with the involvement of ABCA12 in ceramide transport contributes to a growing body of
evidence for the role of ceramide dysfunction in the pathogenesis of PSEK. Finally, we present
evidence that mosaic KID syndrome may present with acantholytic dyskeratosis.
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INTRODUCTION
Mosaicism in Dermatology
Genetic mosaicism underlies a number of inherited and acquired dermatologic
disorders. In inherited genodermatoses, while abnormalities of the skin can be the most striking
feature, they are often associated with abnormalities of other end organs. The tissues affected
and burden of skin and systemic disease are determined both by the exact mutation and the
differentiation potential of the affected precursor. Mutations arising earlier in embryogenesis
lead to more widespread defects due to the greater differentiation potential of the mutated
cell. While small epidermal nevi result from a late mutation in an ectodermal precursor,
systemic involvement appears when mutations arise in embryonic progenitors which can
populate multiple germ layers.1-3 Some mosaic disorders, such as neurofibromatosis or
xeroderma pigmentosum, require both a genetic susceptibility to disease as well as a somatic
mutation to give rise to a clinically apparent phenotype.4-7 Mosaicism also underlies various
dermatologic conditions acquired in adulthood, as a result of somatic mosaicism during the
lifespan. This category includes all adult cutaneous malignancies as well as benign tumors, the
behavior of which can often be predicted by the genetic changes underlying the lesions.
Mosaicism falls into two broad categories: epigenetic and genomic mosaicism.8 These
refer to cellular mosaicism caused by non-coding changes to genetic expression and changes in
the genomic code respectively. One well-known example of epigenetic mosaicism occurs via Xinactivation, in which one of the two X chromosomes within female offspring is inactivated by
DNA methylation due to differential expression of XIST.9,10 Consequently, in X-linked genetic
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disorders, females can be mosaic with only a subset of their cells expressing disease.11-13 This is
readily observed in X-linked genodermatoses such as Incontinenitia pigmenti, Goltz syndrome,
and MIDAS syndrome, where the skin lesions are found along Blaschko's lines that demarcate
the dorsoventral migration patterns of ectodermal development.14-16
Genomic mosaicism can result from postzygotic mutations, which, based on their timing
during embryogenesis, can generate somatic, gonadal, or gonosomal mosaicism.17 Somatic
mosaicism affects only somatic tissue, gonodal mosaicism affects only the germline, and
gonosomal mosaicism affects both somatic tissue and the germline. While gonadal mosaic
individuals may not exhibit a phenotype, the offspring from mutant germ cells will be affected
by disease, and will have an apparent de novo mutation in all cells. Somatic mutations are
instead limited to the soma, and subsequent generations are spared due to absence of
mutation in germ cells. Finally, gonosomal mutations occur at a step in embryogenesis
preceding the development of the germline and permit the mutation to appear in portions of
both the soma and germ cells.18 In these cases, offspring are often more severely affected than
the proband, since they carry the disease-causing mutation in all, rather than a subset, of their
somatic cells.
Advances in Characterizing Mosaic Disorders
While mosaic disorders have historically been difficult to study due to issues such as
admixture, recent advances in sequencing technology have made comprehensive genetic
investigation of mosaic disorders feasible. Disorders arising via copy number variation or
chromosome rearrangements can be studied using microarray-based techniques such as array-
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based comparative genomic hybridization (CGH) and genome-wide single nucleotide
polymorphism (SNP) genotyping. Unlike cytogenetic analysis, which is limited to assessment of
one metaphase cell at a time, array CGH and SNP genotyping survey many cells at once without
limitation to one cell-cycle stage (metaphase).19-23 Such array-based techniques are also highly
sensitive, detecting genotype variations in as low as 5% of a mutant fraction.21
Next-generation sequencing (NGS), which became commercially available in 2005, has
dropped both the cost and the time required to sequence samples compared to traditional,
capillary-based Sanger sequencing. Whole-exome sequencing (WES) and whole-genome
sequencing (WGS) now costs hundreds or approximately a thousand dollars, respectively,
orders of magnitude less than the cost required during the completion of the human genome
project. Most NGS platforms employ similar setups using short DNA fragments, either via
capture of genomic fragments using a set of targeted barcoded primers (WES) or direct DNA
fragmentation (WGS). These fragments undergo amplification and parallel sequencing to
generate short sequence reads, which are then aligned to the human reference genome to
identify novel single nucleotide variants (SNVs), rearrangements, or copy number changes.24-26
For somatic mosaic disorders, comparative paired sequencing is performed using blood, saliva,
normal skin DNA as a control, in order to identify those mutations that are exclusive to or
enriched in a lesion.27
Novel mutations in previously uncharacterized diseases have been successfully
identified using NGS. While comprising only about 1% of the human genome, coding DNA (the
"exome") is estimated to host up to 85% of disease-causing mutations; hence, limiting
sequencing to the exome is a cost-effective method for gene discovery.28-30 In cases where WES
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fails to identify a candidate variant, WGS and/or whole-transcriptome shotgun sequencing
(WTSS) can be used. In WGS, introns and intergenic DNA can also be assessed, allowing
identification of whole gene inversions or mutations in regulatory domains.31 WTSS provides
the sequence and level of expression of cellular mRNA, permitting detection of splicing variants
and regulatory untranslated region (UTR) mutations.32-34 These techniques are often employed
in tandem; for example, a candidate mutation detected via WGS upstream of a gene may be
found with decreased expression of the gene via WTSS, suggesting a disruption of a potential
promoter or enhancer region.
Despite these advances, mosaic disorders can still be challenging to investigate
principally because of the very nature of these conditions: not all cells carry the mutation of
interest. Indeed, one of the most common challenges to accurate diagnosis is the need to
sample affected tissue rather than blood as the mutation causing cutaneous manifestations
may have occurred after the divergence of ectodermal and mesodermal precursors. Even when
present, the mutation may be present at such a low allele fraction as to be undetectable using
standard sequencing approaches.
Another barrier to genetic diagnosis is admixture of affected cells with wild-type stromal
or infiltrating immune cells, leading to a low mutant allele fraction within affected tissue
DNA.35,36 Approaches to overcome admixture include high depth sequencing or techniques
which can enrich affected cells prior to sequencing. Increasing the depth of sequencing involves
increasing the fold coverage of each genomic segment, thereby improving the likelihood of
mutation detection.25,26,37,38 An alternative, cost-effective, approach, utilizes targeted gene
panels, which focus on specific genes. By reducing the targeted interval, it becomes cost-
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effective to sequence to depths greater than 500-fold coverage, far greater than the standard
depths of whole-exome and whole-genome sequencing.39-41 While this approach is helpful for
diagnostic assays, it can fail to identify mutations in genes not previously associated with the
disease. In such cases, laser-capture microdissection or cell culture can isolate affected cell
types, enriching the mutant allele fraction in WES and WGS.42-51
Epidermolytic Acanthoma
Epidermolytic acanthoma (EA) is a rare, benign, acquired lesion demonstrating
hyperkeratosis, hypergranulosis, acanthosis, and a distinct histopathologic pattern of epidermal
degeneration on histopathology commonly referred to as a pattern of epidermolytic
hyperkeratosis (EHK).52 While lesions are typically solitary, EA may also arise as multiple, or, in
rare cases, disseminated lesions.53,54 EA occurs anywhere on the body, but lesions that arise on
the genitalia, which are interestingly more common in men than women, can be especially
distressing due to frequent misdiagnosis as condyloma accuminatum.55-57 Nevertheless, human
papillomavirus (HPV) typing is typically negative in EA.58,59
Based on the nearly identical histologic pattern of EA and EHK-associated inherited
dermatoses such as epidermolytic ichthyosis and ichthyosis bullosa of Siemens, some have
speculated that EA is a somatic mosaic form of these generalized cutaneous disorders.
Epidermolytic ichthyosis and ichthyosis bullosa of Siemens arise as a consequence of mutations
in the genes encoding keratin 1, 10, or 2e.60-62 Indeed, in an immunohistochemical analysis of
EA, Cohen et al demonstrated that the expression of keratin 1 and 10 was diminished in the
altered granular layer in comparison to the normal-appearing perilesional granular layer.63
Nevertheless, previous efforts to sequence the KRT1 and KRT10 genes from DNA extracted
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from these lesions have not identified mutation, likely due to the utilization of methods that are
underpowered to detect somatic mutation.64 In this work, we present evidence for the genetic
mechanism causing EA.
Progressive Symmetric Erythrokeratodermia
Erythrokeratodermia variabilis et progressiva (EKVP) is a disorder of keratinization
presenting in infancy with fixed hyperkeratotic plaques and transient erythema. EKVP was
previously classified as two distinct conditions: progressive symmetric keratodermia (PSEK),
characterized by symmetrically distributed, well-demarcated, erythematous, hyperkeratotic
plaques which slowly expand over time; and erythrokeratodermia variabilis (EKV), which has a
milder presentation characterized by infantile onset of transient erythematous patches and
slow-progressing hyperkeratotic plaques.
Mutations in a number of genes encoding connexin proteins, including GJB3,65 GJB4,66
and GJA1,67 have been identified in EKV. Mutations in KDSR,68 encoding an enzyme in the
ceramide synthesis pathway, KRT83,69 encoding a type II keratin expressed strongly in
keratinocytes, LOR,70 encoding loricrin, a protein composing ~70% of the cornified envelope,
and GJB4 have also been identified in PSEK.71 There is also evidence of further genetic
heterogeneity in EKV, as there have been multiple reported EKV cases without mutation in GJB3
or GJB4. In this work, we present three cases of PSEK with a previously unreported genetic
cause.
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Mosaic Acantholytic Dyskeratosis
Acantholytic dyskeratosis refers to a classic histopathologic pattern of acanthosis,
papillomatosis, hyperkeratosis, acantholysis, suprabasal clefting, as well as dyskeratotic cells in
the upper layers of the epidermis. This histologic pattern, in childhood, is typically associated
with one of two conditions: Darier's disease and Hailey-Hailey disease. The primary cellular
mechanism for epidermal dysfunction in these disorders is a deficiency in cellular adhesions, as
electron microscopy reveals loss of desmosomal attachments in affected tissue.72 Interestingly,
both of Darier's disease and Hailey-Hailey disease are caused by mutations in genes encoding
calcium channel pumps, ATP2A2 and ATP2C1 respectively.73,74 While the precise pathological
mechanism is not fully understood, evidence suggests that calcium signaling is critical for the
creation of a polarized epithelium and for the assembly of functional desmosomes.75,76 Further
elucidation of the mechanism by which calcium signaling is perturbed by ATP2A2 and ATP2C1
may ultimately lead to insights that guide future therapeutic interventions for acantholytic
disorders.
Notably, while these diseases are classically generalized disorders, both Darier's disease
and Hailey-Hailey disease may also present in segmental patterns, caused by post-zygotic
mutations in ATP2A2 and ATP2C1 respectively.77,78 These patients have the same symptoms
and histopathology associated with the generalized disease, but localized to lines of Blaschko.
While this is not the case in for ATP2A2 and ATP2C1 mutations, mosaic presentations can be
driven by genetic mutations that are lethal if constitutionally expressed.2,79,80 These cases can
often provide insights about the pathogenesis of the more common constitutional disorders. In
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this work, we present a genetic analysis of a mosaic presentation of childhood acantholytic
dyskeratosis not caused by ATP2A2 or ATP2C1 mutations.
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STATEMENT OF PURPOSE
1) To evaluate the genetic changes associated with three inherited and acquired mosaic
cutaneous conditions
a) Epidermolytic acanthoma
b) Progressive symmetric erythrokeratodermia
c) Mosaic acantholytic dyskeratosis
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METHODS
Case Identification
We retrieved all specimens with a diagnosis of epidermolytic acanthoma between
January 1st, 2013 and September 1st, 2018 from departmental archives, with appropriate IRB
approval. All specimens had been formalin-fixed and embedded in paraffin, with slides having
been stained with hematoxylin and eosin (H&E). Inclusion criteria included keratosis with either
a flat or inverted pattern, with greater than 50% epidermal area showing EHK. Twenty-four
cases were found meeting these criteria with 3 cases subsequently excluded due to insufficient
tissue remaining in the block.
Cases with a clinical diagnosis of either PSEK or EKV as well as a case with a mosaic
presentation of acantholytic dyskeratosis were referred by academic dermatologists. The study
was approved the Yale Human Investigation Committee, and informed parental permission was
obtained in prior to study.
Analysis of Archival Specimens (Epidermolytic Acanthoma)
After identification of the affected component of the samples using prepared H&E
slides, genomic DNA (gDNA) was isolated from 1mm cores of affected paraffin embedded
tissues using the FFPE DNeasy Micro Kit (Qiagen). Our discovery cohort included 3 samples of
EA in which gDNA from affected skin was sheared and bar-coded then sent for whole-exome
capture, which was performed by the Yale Center for Genome Analysis (IDT xGen Exome
Research Panel V1.0). Using 100bp paired-end reads with samples pooled at 4 per lane, Illumina
HiSeq4000 instruments were used for high-throughput sequencing. Reads were then aligned to
the human reference genome (UC Santa Cruz Genome browser, hg19) using the Borrows-
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Wheeler Aligner. Reads were trimmed, polymerase chain reaction (PCR) duplicates were
removed using Picard (Broad Institute) and resulting BAM files were calibrated using the
Genome Analysis Toolkit (Broad Institute). Mutect2 was used to identify single-nucleotide
variants (SNVs) and indels. Variants were filtered in Microsoft Excel in order to exclude those
with a prevalence of greater than 1% in the exome Aggregation Consortium repository. Reads
were then examined with the Integrative Genomics Viewer (Broad Institute) in order to exclude
variants resulting from alignment error or miscalls. Variants were additionally screened within
the Catalogue Of Somatic Mutations In Cancer (COSMIC). Mutation confirmation was
performed using RFLP analysis. Seventeen additional cases were screened using PCR
amplification followed by Sanger sequencing of known mutation hotspots in the rod domains of
KRT1 (exons 2, 7, and 9), KRT10 (exons 1 and 6), and KRT2A (exons 1 and 7). The primers used
for these screens are listed in Table 1. Mutation negative samples were screened via a rapid
assay exploiting the fact that KRT10 point mutations (R156H, R156S, R156C, and R156P)
obliterate an AciI enzymatic digestion site. gDNA isolated from 1mm cores of affected tissues
was amplified using our KRT10 exon 1 primers (Table 1) and the resulting amplicon was
digested with the AciI enzyme for 2 hours at 37°C. Following digestion, the DNA was visualized
on a 2% agarose gel. DNA from the mutant 446 base-pair fragment was extracted using the
Monarch DNA Gel Extraction Kit (New England Biolabs), PCR amplified, and Sanger sequenced.
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Table 1. Primers used for PCR amplification of target exons
Amplicon
Target Gene
KRT10

KRT1
KRT2A

Exon

Forward Primer (5'-3')

Reverse Primer (5'-3')

1
6
1 – mutant
fragment
2
7
9
1
7

CCTCTCAGTATATAAAGGCTTGTCACTG

CACACTTGCTGGATGAAGATTGC

AACTACAGTCCCAACTGGCCTTG

GGGTGAGGTCACATTCGGTTATC

TGGTGGATTTGGAGGAGATG

GAGTTGCCATGCTTTTCATACC

CCTTCCAAGCCCTCTCTGAATTAAC

CTACATGCTGCTTCATGATCTTAGC

GACTCATTATTGGCCTCACTGGAG

AAGAGCCTTGCAGCCAATGAAG

GGATTAAGTTTCAGATTAAGTGCATTGG
CTTCCAGCTTCTCCTGCTTG

CCATAGCTCTTTTCTCCGGTAAGG
TATGGGAAATGTAACCCACAAAG

ACACCTCTGCTCTCTGTCCG

GACAGGGAAAGCAGAGAATGG

Analysis of Patient Tissue (PSEK and Mosaic Epidermolytic Dyskeratosis)
For each case, genomic DNA from blood was isolated via a standard phenol-chloroform
protocol while DNA from saliva was isolated via the Saliva DNA Isolation Reagent Kit (Norgen).
After shearing and barcoding DNA, whole-exome capture was performed by the Yale Center for
Genome Analysis (IDT xGen Exome Research Panel V1.0) using 100bp paired-end reads, and
sequenced using Illumina HiSeq4000 instruments. Reads were aligned to a human reference
genome (UC Santa Cruz Genome browser, hg19) using the Borrows-Wheeler Aligner (BWAMEM. Reads were trimmed and polymerase chain reaction (PCR) duplicates were removed
using Picard (Broad Institute), and resulting BAM files were calibrated using the Genome
Analysis Toolkit (GATK, Broad Institute). HaplotypeCaller and ANNOVAR was employed to
identify and annotate coding variants. Common and non-damaging variants including those
occurring with greater than 1% prevalence in control population datasets including ExAC, the
1000 Genomes project, Exome Variant Server, and dbSNP were omitted, and remaining reads
were visualized with the Integrative Genomics Viewer (Broad Institute) to exclude variants
resulting from alignment error or miscalls. Candidate mutations were verified via PCR (KAPA
Biosystems) and Sanger sequencing. For the case of mosaic acantholytic dyskeratosis, lesional
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keratinocytes were cultured from skin biopsy samples via overnight dispase digestion followed
by isolation of keratinocytes from the resulting epidermal sheet using 0.05% trypsin – 2% EDTA.
Cells were split and propogated in EpiLife (Invitrogen) when individual colonies of keratinocytes
were established. RNA from cultured keratinocytes was isolated and paired RNA-sequencing
was performed comparing isolated RNA to RNA obtained from a patient blood sample. Cultured
patient keratinocytes were also compared with wild-type keratinocytes via a dispase
mechanical dissociation assay whereby keratinocytes were incubated with 2.4U/mL of dispase
(BD Biosciences) at 37°C to generate keratinocyte monolayers that were then subjected to
mechanical stress by pipetting.81 The effect of mechanical stress on the monolayers was
compared via a two-tailed t-test with statistical significance at the p<0.05 level.
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RESULTS
Epidermolytic acanthoma
The demographic characteristics of our analytic sample are presented in Table 2. The
sample included 11 women and 9 men, with 3 anogenital cases and the remainder from
extragenital sites. All cases were adults with a median age of 66 and an age range of 42 to 84
years. The most common favored clinical diagnosis was squamous cell carcinoma (40%),
followed by verruca vulgaris (25%), and seborrheic keratosis (25%).
Table 2. Characteristics of the epidermolytic acanthoma study cohort.
Subject
Anatomic
Age Sex
Favored Clinical Diagnosis
Mutation Identified
ID
Location
EA1
74
F
Extragenital
Squamous cell carcinoma
N/A
Squamous cell
EA2
81
F
Extragenital
Insufficient DNA for RFLP analysis
carcinoma/verruca vulgaris
Seborrheic keratosis/ verruca
EA3
61
F
Extragenital
None
vulgaris
EA4
81
M Extragenital
Squamous cell carcinoma
None
Verruca vulgaris/squamous cell
EA5
76
F
Extragenital
KRT10: c.466C>T, p.Arg156Cys
carcinoma
EA6
45
F
Extragenital
Acrochordon
N/A
EA7
64
F
Extragenital
Seborrheic keratosis
None
EA8
42
F
Anogenital
Seborrheic keratosis
KRT10: c.466C>T, p.Arg156Cys
Actinic keratosis/squamous cell
EA9
73
F
Extragenital
KRT10: c.466C>T, p.Arg156Cys
carcinoma
EA10
53
F
Extragenital
Basal cell carcinoma/atypia
KRT10: c.466C>T, p.Arg156Cys
EA11
66
M Extragenital
Squamous cell carcinoma
KRT10: Arg156, NOS
EA12
66
M Extragenital
Dermatofibroma
Insufficient DNA for RFLP analysis
Verruca vulgaris/sebborheic
EA13
58
F
Extragenital
KRT10: Arg156, NOS
keratosis
EA14
63
M
Anogenital
Milia/cyst/verruca vulgaris
None
EA15
77
M Extragenital
Seborrheic keratosis
Insufficient DNA for RFLP analysis
Basal cell
EA16
89
M Extragenital
N/A
carcinoma/seborrheic keratosis
Squamous cell carcinoma/basal
EA17
71
M Extragenital
N/A
cell carcinoma
EA18
60
M
Anogenital
Nevus
None
EA19
73
M Extragenital
Actinic keratosis
Insufficient DNA for RFLP analysis
EA20
44
F
Extragenital
Squamous cell carcinoma
Insufficient DNA for RFLP analysis
F – Female, M – Male, N/A – Not applicable: DNA of insufficient quality for PCR amplification, RFLP – Restriction
Fragment Length Polymorphism, NOS – not otherwise specified

DNA from four samples (EA1, EA6, EA16, and EA17) was of insufficient quality for PCR
amplification. WES of gDNA from EA3, EA8, and EA10 was performed (Table 3) and identified a
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KRT10 c.466C>T, p.Arg156Cys mutation in EA8 and EA10 (Table 3). WES also identified a low
allele frequency KRT9 c.226G>A, p.Gly76Arg mutation in EA3. No other candidates were
identified with COSMIC screening for cancer-associated mutations. KRT10 mutations were
confirmed using RFLP analysis with the AciI enzyme (Figure 1). Given that the mutation
disrupted the cutting sequence of the AciI restriction enzyme, AciI digestion of the wild-type
PCR product was expected to yield a close pairing of bands at 355 and 317 base pairs in length,
while the digestion of the c.466C>T mutant product was expected to yield a band at 446 base
pairs in addition to the 317 base-pair band. Sanger sequencing screens of exons 1 and 6 of
KRT10 as well as exons 2, 7, and 9 of KRT1 and exons 1 and 7 of KRT2A in 13 additional cases
were evaluated with no mutations identified. For 8 of these cases with remaining lesional
gDNA, RFLP analysis was performed for KRT10 p.156 mutations, revealing p.156 mutations in 4
additional lesions (Figure 2). Gel DNA extraction and sequencing of the mutant fragment was
successful for EA8 and EA10 as well as for EA5 and EA9, revealing the KRT10 c.466C>T,
p.Arg156Cys mutation in all four cases (Figure 3).

Table 3. Results of whole-exome sequencing analysis.
Subject ID

Mutation

EA3
EA8
EA10

KRT9 c.226G>A, p.Gly76Arg
KRT10 c.466C>T, p.Arg156Cys
KRT10 c.466C>T, p.Arg156Cys

Number of Reads
Reference
170
162
179

Non-Reference
10
48
30

Non-Reference
Allele Fraction
0.06
0.23
0.14

Among the six cases with identified mutations, there were five female patients and one
male with an age range of 42 to 76. One of the lesions arose in a genital location while the
remaining five were located on extragenital sites. Histopathologic analysis of the cases revealed
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were 2 cup-shaped lesions and 4 flat lesions. All cases demonstrated epidermal acanthosis,
hyperkeratosis, and characteristic epidermolytic hyperkeratosis (Figure 3).
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Progressive Symmetric Erythrokeratodermia
Case 1 was a six-month-old girl presented with well-demarcated, erythematous,
hyperkeratotic plaques symmetrically distributed on the face, chest, abdomen, and extremities
as well as diffuse hyperkeratosis on the plantar aspect of the feet. She was born at term with no
complications and had no family history of dermatologic disorders. She was treated with
emollients with no notable improvement in the lesions.
Case 2 was a 9-year-old girl who initially presented at age 19 months with a one-year
history of well-demarcated red-brown asymptomatic rough plaques on the trunk, extremities,
face and neck (Figure 4A). Initially some lesions were circinate. The lesions never involved the
palms or soles. She did not have transient erythematous patches. Hair, teeth and nails were
normal. Her father had fairly typical ichthyosis vulgaris with mild palmoplantar hyperkeratosis
and flexural sparing.
Case 3 was a 17-month-old boy who presented with mild temporal hair thinning as well
as symmetric, erythematous plaques on the cheeks and erythematous plaques, some of which
had double-edged scale (Figure 4B). The patient's parents reported increased erythema with
exposure to heat and sunlight. He was born at term with an uncomplicated pregnancy and had
met all developmental milestones. Besides a maternal grandmother with eczema, there was no
other family history of dermatologic conditions. He has trialed CeraVe SA, VaniplyTM, and a
homemade lotion (composed of shea butter, coconut oil, rosehip seed oil, olive oil, grapeseed
oil, glycerine, Vanicream, and vitamin E oil), with some improvement.
In all three cases, we identified a compound heterozygous mutation in the ABCA12 gene
(Table 4). Case 1 had a frameshift mutation (c.2033_2036delATCA, p.N678Rfs*10) on one allele
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of ABCA12 and a splice site mutation (c.2866-8T>A) on the other. In case 2, each allele of
ABCA12 harbored independent missense mutations (c.2531A>G, p.D844G; c.5812C>T,
p.P1938S). Case 3 had a nonsense mutation on one allele of ABCA12 (c.5787T>G, p.Y1929*) and
a missense mutation on the other (c.6852G>C, p.E2284D).

Table 4. Characteristics of the PSEK study cohort.
Age at
Compound Heterozygous
Case
Sex
Presentation
Mutation 1
ABCA12 c.2033_2036delATCA,
1
6 mo.
F
p.N678Rfs*10
ABCA12 c.5787T>G,
2
9 yo.
F
p.Y1929*
ABCA12 c.2531A>G,
3
17 mo.
M
p.D844G
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Compound Heterozygous
Mutation 2
ABCA12 c.2866-8T>A,
splice site
ABCA12 c.6852G>C,
p.E2284D
ABCA12 c.5812C>T,
p.P1938S

DNA Source
Blood
Saliva
Saliva

Mosaic Acantholytic Dyskeratosis
The case was a male infant born at 39 weeks gestational age following a pregnancy
complicated by pre-term labor, initially presenting with red, eroded, macerated plaques of the
scrotum, perianal area, and inguinal folds bilaterally, with later progression to the axillae and
distal toes (Figure 5). His initial laboratory tests were notable for a borderline low zinc level (56
µg/dL) which resolved with supplementation, and he was found to have moderate-to-severe
sensorineural deafness but never developed ocular abnormalities. Skin biopsies of multiple,
independent sites revealed suprabasal acantholytic dyskeratosis (Figure 6). Over the following
seven years, his cutaneous eruption spread to include the posterior trunk, lower extremities,
and posterior scalp, ultimately involving approximately 30% of his body surface (Figure 7).
Multiple topical and systemic therapies were administered without significant improvement,
including cyclosporine, methotrexate, naltrexone, zinc, isotretinoin, acitretin, dapsone, and
erythromycin. Trials of nbUVB phototherapy, photodynamic therapy, pulsed-dye laser and
botox therapy were unsuccessful. He experienced recurrent infection and chronic bacterial
colonization as well as chronic pain during this time.
Genetic testing for Darier-White and Hailey-Hailey disease found no mutations in
ATP2A2 or ATP2C1. Whole-exome sequencing (WES) of blood revealed no novel pathogenic
mutations. Subsequent paired RNA sequencing revealed a novel somatic mutation in GJB2
(c.T83A, p.L28H) within affected tissue. This mutation was confirmed to be absent in both
parents. After culturing keratinocytes from lesional tissue, a dispase mechanical dissociation
study revealed the patient's cells to have markedly perturbed adhesion compared to a wildtype control (Table 5).
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Table 5. Characteristics of the epidermolytic acanthoma study cohort.
Mechanical
Stress
No Pipet
Stress
20x Pipet
Disturbance
40x Pipet
Disturbance

Number of Fragments
Patient
Wild-Type
Keratinocytes Keratinocytes
Well 3
Well 1

Wild-Type
Keratinocytes
Well 2

Wild-Type
Keratinocytes
Well 3

p-value
of t-test

1

1

1

0.010

112

5

3

5

<0.001

792

24

20

16

<0.001

Patient
Keratinocytes
Well 1

Patient
Keratinocytes
Well 2

5

8

10

92

132

892

1024
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DISCUSSION
Epidermolytic Acanthoma
Herein, we present novel evidence that epidermolytic acanthoma is caused by hotspot
mutations in KRT10. The nearly identical histology of epidermolytic hyperkeratosis in EA and
inherited EHK-associated dermatoses had previously suggested that EA may be a somatic
mosaic variant of these conditions. Indeed, the KRT10 p.Arg156Cys mutation identified by WES
in two of our cases was among the first mutations detected in epidermolytic ichthyosis.60 Our
analysis also revealed that mutations in this KRT10 Arginine 156 hotspot are common in EA,
with mutations identified in over 65% of cases analyzed via RFLP. It is believed that the high
mutation frequency at the Arg156 site is caused by the presence of a CpG sequence which
commonly undergoes 5' cytosine methylation followed by spontaneous deamination, resulting
in either a C>T or G>A transition depending on whether the coding or non-coding strand is
affected.82-85 The Arg156 site, part of the conserved 1A rod domain of keratin 10, has a critical
functional role and expression of basal keratin equivalents of the keratin 10 Arg156Cys and
Arg156His mutants in cultured keratinocytes results in disruption of the keratin network.86
While WES also detected a KRT9 mutation in one sample, this is unlikely to be pathogenic as it
is not in a conserved position and lies in the head domain of the keratin 9 protein.
Our results also highlight the difficulties in genetic analysis of mosaic disorders. In
contrast to the inherited EHK-associated dermatoses, wherein germline mutation results in the
genetic change being readily detectable in DNA extracted from the blood via Sanger
sequencing, genetic changes underlying mosaic disorders are detected only in the lesional
tissue itself.87,88 Even when lesional tissue is utilized, admixture from neighboring cell types, as
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well as wild-type cells of the same lineage, can lead to a low mutant allele fraction that cannot
be readily detected via traditional capillary-based sequencing technologies.27 Indeed, admixture
from neighboring wild-type cells is the likely reason that the mutations identified via RFLP
analysis were not detected via our initial Sanger sequencing screen. This phenomenon may also
have contributed to the lack of detected mutations in previous efforts to sequence
epidermolytic acanthoma, which utilized Sanger sequencing to screen coding regions of the
KRT1 and KRT10 gene in a case of genital EA.64 In contrast to capillary-based sequencing
methods, WES technology permits deeper sequencing of certain regions of the genome,
allowing the detection of mutations present in smaller allele fractions.
These limitations in genetic analysis of mosaic disorders are also likely to underlie the
mutation-negative samples in our study. In cases for which mutations could not be identified
via RFLP analysis, it is possible that admixture led to our inability to detect a mutation in one of
the Sanger sequencing screened exons in the KRT10, KRT1, or KRT2A genes known to harbor
hotspot mutations causing Epidermolytic ichthyosis and ichthyosis bullosa of Siemens.60-62
Alternatively, EA in these cases may be caused by mutations in either a gene not yet identified
as a cause of EHK or in a portion of the KRT10, KRT1, or KRT2A genes not captured in our
screen. Additionally, in the case of EA3, for which WES did not reveal a likely pathogenic
mutation, we were likely limited by the depth of our sequencing (in this case a median depth of
146). It is possible that this was not a sufficient read depth to detect mutation in this case due
to significant admixture. Indeed, cancer panels which also have to contend with substantial
admixture in tumor samples, can utilize average sequencing depths over 1000X in order to
detect pathogenic variants.41,89,90
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The finding of somatic mosaic nevi recapitulating the histological findings of systemic
conditions with the same underlying mutations may help to guide future genetic analysis of
these lesions. Already, genetic analysis of a case of papular acantholytic dyskeratosis (PAD),
which demonstrates the same histologic findings of acantholytic dyskeratosis as seen in Darier
disease, revealed mutation in ATP2A2, the same gene found to be mutated in Darier
disease.91,92 Interestingly, the anatomic predilection of both EA and PAD for genital areas may
be attributable to the trauma from repeated scratching of the area unmasking lesions due to
somatic mosaicism.
Our study is limited by a lack of specific mutation information for two out of the six
cases which we identified as having hotspot mutations in the KRT10 Arginine 156 hotspot.
Interestingly, the first study to report the p.Arg156Cys mutation in epidermolytic ichthyosis also
utilized AciI restriction enzyme digestion and found that the restriction site was additionally
interrupted by other mutations in this hotspot, namely c.467G>A (p.Arg156His) and c.467G>T
(p.Arg156Leu).60 Thus, while we can conclude that the four Sanger sequenced cases harbored
p.Arg156Cys mutations, it is possible that the other samples with the restriction enzyme
digestion site polymorphism had another mutation at the Arginine 156 hotspot.
In this analysis, we demonstrate that somatic mutation of a KRT10 hotspot underlies
epidermolytic acanthoma. While this was previously suspected based on the histological
similarity of EA to epidermolytic ichthyosis, this had not been previously confirmed via genetic
study. As sequencing technologies progress and make analysis of mosaic lesions more feasible,
genetic analysis will reveal mutations underlying additional disorders.
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Progressive Symmetric Erythrokeratodermia
Our findings establish ABCA12 as a novel cause of the EKV/PSEK disease spectrum.
Mutations in the connexin genes, which are the most commonly implicated in EKV, lead to
impaired cellular trafficking of the gap junction proteins as well as cell death, some via an
endoplasmic reticulum-stress mediated pathway.67,93,94 Macroscopically, the clinical phenotype
of EKV may result from defects in the permeability of the cornified envelope, as suggested by
the discovery of mutation in the gene encoding the loricrin protein, the primary constituent of
the cornified cell envelope.70 Indeed, the significance of a compromised stratum corneum
integrity disruption leading to the clinical phenotype was further supported by later work that
described mutations in KDSR in three patients with PSEK.68 KDSR encodes the enzyme
responsible for catalyzing the production of dihydrosphingosine, a key metabolite of the de
novo ceramide synthesis pathway.95 Like loricrin, ceramides are also a critical component of
the cornified cell envelope, as they covalently bind the protein layer to form the intercellular
lipid lamellae, preventing transepidermal water loss.
Our implication of ABCA12 in the pathogenesis of PSEK further consolidates the role of
ceramide dysfunction in the disease pathogenesis. ABCA12 is a member of the ATP-binding
cassette (ABC) transporter genes which encode proteins that bind ATP in order to transport a
number of different substrates across the cell membrane.96 Within the ABC superfamily,
ABCA12 is a member of the lipid-transporting ABCA subfamily.97 ABCA12 is involved in ceramide
transport and is necessary for the production of functional skin linoleic esters of long chain ωhydroxyceramides from their glucosyl ceramide precursors.98 Mouse experiments have
demonstrated that the loss of ABCA12 leads to lamellar granule abnormalities, defective
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ceramide distribution, hyperkeratosis, and severe skin barrier defects.98,99 Indeed, ABCA12
mutations have been reported as the cause of harlequin ichthyosis and lamellar ichthyosis type
2.100,101
In conclusion, we find compound heterozygous mutations in ABCA12 in three patients
presenting with PSEK. In doing so, we contribute to the growing evidence for the role of
ceramide dysfunction in the pathogenesis of PSEK, further supporting this process as a potential
therapeutic target.
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Mosaic Acantholytic Dyskeratosis
This case illustrates a novel cause of acantholytic dermatitis in childhood and further
underscores the utility of advanced genetic analysis in undiagnosed skin disorders. Mutations in
GJB2, which encodes the connexin 26 protein, are known to cause Keratitis-Ichthyosis-Deafness
(KID) syndrome, suggesting that the patient had a mosaic form of KID syndrome, consistent
with findings of sensorineural deafness and recurrent infection, but with an unexpected
histologic presentation of suprabasal acantholytic dyskeratosis.
These findings also provide new insights into the pathogenesis of acantholytic disorders.
As in the case of Darier's disease and Hailey-Hailey disease, the GJB2 mutation underlying this
acantholytic disorder led to a desmosomal defect causing impaired cell-cell adhesion, as
demonstrated by the displace dissociation assay results. However, unlike the ATP2A2 and
ATP2C1 genes that encode calcium channel pumps, the connexin 26 protein encoded by GJB2 is
a component of gap junctions. While the importance of calcium to promote desmosomal
assembly and stability is well-characterized, work characterizing the interactions between gap
junctions and desmosomes is relatively less established.102 Interestingly, much of the current
understanding of interactions between desmosomes and gap junctions, predominantly focused
on work studying cardiac cells, suggests that functioning desmosomes are required for
maintenance of gap junctions.103-108 Furthermore, desmoglein-2 and connexin 43 have been
demonstrated to have interactions via pull-down assays.109 Indeed, there may be multiple
mechanisms for the maintenance of gap junctions by desmosomes as previous work has
revealed that disturbances in desmoplakin lead to connexin loss both via perturbed targeting of
connexins to the cell membrane and via Ras/MAPK-mediated connexin degradation.103,104
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However, in the case of the patient in the present work, it was a mutation in a gap junction
gene which led to desmosomal defects, suggesting that desmosomal function may also be
dependent on functional connexin proteins.
In conclusion, in the present work, we present a case of a childhood acantholytic
dyskeratosis caused by mutation in the gap junction gene GJB2. This work provides further
insights into the mechanism of the epidermal cellular adhesion machinery. Further elucidation
of the molecular functions and relationships of the components of these structures may allow
for therapeutics for a wide range of acantholytic and blistering disorders including Darier's
disease, Hailey-Hailey disease, Epidermolysis bullosa, and even adult disorders such as
pemphigus vulgaris and foliaceus.
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Future Directions of Research in Mosaic Cutaneous Disorders
While marked progress that has been made in identifying the genetic basis of many
cutaneous mosaic disorders, many remain without a known etiology. These include numerous
proliferative/hamartomatous disorders and linear inflammatory disorders. In addition to
helping to clarify the pathogenesis of these conditions, genetic investigation of these discrete
mosaic disorders may help to provide insight into the genetic pathogenesis of more common
generalized disease.
A common linear inflammatory disorder, lichen striatus (LS), presents in children as a
self-limited, unilateral, Blaschkoid lesion, with infiltrative CD8+ lymphocytes noted on
histopathology.110-114 Given its distribution and the lymphocytic infiltrate, LS may represent an
autoimmune response to a mutant keratinocyte clone.115,116 It is unclear whether mutant
clones are ultimately eliminated, as LS rarely relapses.115
Inflammatory Linear Verrucous Epidermal Nevus (ILVEN) is characterized by a
Blaschkoid distribution of pruritic, erythematous, verrucous plaques that can be difficult to
distinguish from linear psoriasis. Due to clinical and histological similarities between the two,117125

some have suggested that these are the same disorder, namely, a mosaic manifestation of

psoriasis.126,127 However disparate immunohistochemical markers between psoriasis and ILVEN
suggest them to be distinct entities.128-130
Notably, immune skin disorders considered polygenic in nature can also present in a
Blaschkoid fashion, such as psoriasis (linear psoriasis),131-137 atopic dermatitis,138-140 lichen
planus,141-145 and cutaneous lupus erythematosus.146-149 These cases often develop severe,
treatment-refractory lesions along linear patterns, and later develop more generalized disease.
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Analysis of such Blaschkoid lesions may help to identify the genes that contribute to
susceptibility to these immunologic conditions.
On the other hand, the genetic basis for linear sclerosing disorders such as morphea and
segmental congenital facial dystrophy has been more elusive than for related generalized
conditions. A component of this may be due to the more generalized nature of these
conditions, which occur in multiple locations with a Blaschkoid pattern, leading some to
suggest that individuals with linear morphea have susceptible cells in a mosaic state which go
on to develop the disease when exposed to an undefined trigger factor.150 Generalized
congenital fascial dystrophy, otherwise known as the stiff skin syndrome (SSS), is caused by
germline mutations in the FBN1 gene.151 While the segmental form of SSS is thought to arise
from somatic FBN1 mutations, this has not yet been identified, although a recent case treated
with losartan noted some improvement in skin induration.152,153 Similarly, the blaschkoid
appearance of linear morphea suggests underlying mosaicism.154-156 Linear morphea has been
noted in a case of low-grade mosaic Turner syndrome, although karyotype analysis was
conducted utilizing peripheral lymphocytes rather than a direct lesional biopsy.157 Studies have
indicated familial mutations in LEMD3 and LMNA in cases of Buschke-Ollendorf syndrome and
progeria syndrome respectively that presented with generalized morphea-like changes.158-160
Nonetheless, causative mutations have not yet been identified in linear morphea.
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Therapeutic Implications of Mosaic Cutaneous Discoveries
Advances in the understanding of the genetic mechanism underlying cutaneous mosaic
disorders have provided novel targets for therapeutics. This is well-illustrated by recent
developments in the understanding of the mosaic endothelial cell populations underlying
childhood vascular tumors.
Mutations in IDH are known to cause gliomas, glioblastomas, chondrosarcomas,
intrahepatic cholangiocarcinomas, and hematologic malignancies in addition to spindle-cell
hemangiomas.161 As such, a number of therapeutics currently under investigation, may also be
effective in the treatment spindle-cell hemangioma. Early results from trials of ivosidenib (AG120), a novel inhibitor of mutant IDH1, in IDH1-mutated Acute Myelogenous Leukemia (AML)
indicated an overall response rate of 41.6% and a complete remission rate of 21.6%.162
Similarly, results from early trials of enasidenib (AG-221), a novel inhibitor of mutant IDH2, in
IDH2-mutated AML indicated an overall response rate of 40.3% and a complete remission rate
of 19.3%.163 These agents are currently under study in a number of clinical trials (NCT02074839,
NCT02073994, NCT01915498, NCT02577406, NCT02632708, NCT02677922). Mouse studies
have also shown potential for an IDH1 peptide vaccine,164 which is currently under trial
(NCT02454634, NCT02193347).
Selective inhibition of the Ras-MAPK pathway may provide a novel therapeutic avenue
for childhood vascular lesions, which currently have few effective non-surgical options.165 The
central role of this of this pathway in tumor pathobiology has necessitated the development of
a number of currently available medications, including farnesyl transferase inhibitors such as
salirasib, BRAF inhibitors such as vemurafenib, MEK inhibitors such as trametinib, or ERK
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inhibitors such as ulixertinib, which warrant further study as therapy for childhood vascular
tumors. Indeed, Al-Olabi et al. demonstrated that treatment of AVMs in BRAF-mutant zebrafish
with vemurafenib leads to restoration of blood flow in AVMs where it was previously limited.166

- 35 -

Summary
In the present work, we present the genetic cause of three mosaic cutaneous disorders:
epidemolytic acanthoma, progressive symmetric erythrokeratodermia, and mosaic acantholytic
dyskeratosis. These discoveries further our understanding of the pathogenesis of these diseases
and may serve to guide future therapeutic efforts. Future work studying mosaic conditions may
continue to enhance our understanding of both such mosaic presentations and of the
generalized conditions caused by constitutional expression of the genetic changes underlying
them.
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FIGURE LEGEND
Figure 1. Restriction fragment length polymorphism (RFLP) analysis of samples. After digestion
with AciI Enzyme, samples with a mutation in the Arg156 locus had an additional fragment at
446 base pairs (white arrows).
Figure 2. Sanger sequencing traces for gel extracted, mutation-enriched, restriction enzyme
digested fragment.
Figure 3. Histopathologic analysis of epidermolytic acanthomas (A – EA8, B – EA10)
demonstrating classic features of epidermolytic hyperkeratosis (hematoxylin and eosin, total
magnification 200x).
Figure 4. Cutaneous findings of cases 2 and 3 (A/B) demonstrating classic features of
Progressive Symmetric Keratodermia.
Figure 5. Patient's presentation in infancy with red, eroded, macerated plaques of the scrotum,
perianal area, and inguinal folds bilaterally.
Figure 6. Histology of lesional tissue demonstrating subrabasal acantholytic dyskeratosis.
Figure 7. Progression of body surface involvement during the patient's childhood, particularly
on his back and bilateral lower extremities.
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